FlandersBio on Twitter

Follow us on Twitter

Archive for March 2017 - News

Archive for March 2017 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

23.03.2017

First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested. Strong cash position expected to fund operations until mid-2019. read more

Biocartis present at investor event VFB Happening this Saturday 25 March, Antwerp, BE

23.03.2017

This Saturday, Biocartis is present at the investor event VFB Happening, organized by the Flemish Federation of Investors, on the topic Technology. Our CEO Hilde Windels will speak about our continuous technological innovations, and our commitment at Biocartis to give all patients access to treatments with the best possible health outcome, through faster, easier and more accurate (cancer) diagnostics. read more

PHD2 targeting overcomes breast cancer cell death upon glucose starvation

23.03.2017

B55α is one of the regulatory subunits of the PP2A phosphatase. This phosphatases has been associated to the control of many biological functions but the multiplicity of complexes that can be formed by the combination of different subunits renders this protein hard in its understanding. The Massimiliano Mazzone group (VIB-KU Leuven) has recently demonstrated that PP2A/B55α promotes the growth of colorectal cancer, by dephosphorylating PHD2 and modifying its enzymatic properties. PHD2 is a member of a family of enzymes crucial for the cellular response to hypoxia. read more

Novosanis signs an agreement to provide MDxHealth a customized urine collection device

23.03.2017

Novosanis today announced that it signed an agreement with MDxHealth to supply UrNCollect™, a customized version of the Company’s patented urine collection device called Colli-Pee™. The medical device facilitates accurate sample collection for urine-based tests. read more

Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067

22.03.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces initiation of a Phase 1 study with novel potentiator GLPG3067 for cystic fibrosis (CF) in a Phase 1 study. Galapagos is to receive a $7.5 million milestone payment from its collaboration partner AbbVie for this achievement. read more

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

21.03.2017

MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Lab21 Clinical Laboratory's urology clients in the United Kingdom. read more

argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

21.03.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. read more

New toxic pathway identified for protein aggregates in neurodegenerative disease

20.03.2017

Led by professor Ludo Van Den Bosch (VIB-KU Leuven), scientists from Belgium, the UK and the US have identified new processes that form protein “clumps” that are characteristic of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). How these proteins, which can bind RNA in normal cells, stick together has remained elusive until recently, when scientists demonstrated that they demix from the watery substance inside cells, much like oil separates from water. Prof. Van Den Bosch’s team sheds light onto the molecular interactions behind the process in patients with defects in the C9orf72 gene. Their results are featured on the cover of the leading journal Molecular Cell. read more

Pulmocide Raises $30 Million in Series B Financing

20.03.2017

Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, today announced the completion of a $30.4 million Series B financing round. The round was led by new investor SR One and included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc. read more

Kiadis Pharma appoints Jan Feijen as Chief Operations Officer

20.03.2017

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print